Sanuwave Misses Q2 Revenue, Swings to Loss, and Withdraws FY2026 Guidance
SNWV is trading near its 52-week low of $5.77 (4.0% above the low) on light trading volume (0.3× avg).
Summary
Sanuwave reported Q2 revenue of $9.7M, down 3% YoY and just above the high end of its raised guidance, but swung to a GAAP operating loss of $(0.3)M and a net loss of $0.7M. Gross margin slipped to 76.2% from 78.1%. The company withdrew its full-year 2026 guidance, citing CMS reimbursement uncertainty and a proposed rule that could pressure the 97610 code. System sales fell sharply to 82 units from 116 a year ago, though applicator revenue grew 13%. This follows a volatile guidance path—cut in June, raised in July—and now a complete pullback. The withdrawal and CMS headwinds directly threaten the recovery narrative from Q1's positive cash flow.
At the time of this announcement, SNWV was trading at $6.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.6M. The 52-week trading range was $5.77 to $46.59. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.